Products

Karbesat is indicated for the treatment of hypertension. Karbesat is indicated for delaying the progression of renal disease in hypertensive type II diabetics with persistent micro-albuminuria (≥ 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

KARLOR CD is indicated for the treatment of the following types of infections caused by susceptible organisms, in adults and children aged 12 years or older.

Acute bronchitis and acute exacerbations of chronic bronchitis.

Upper respiratory infections, including pharyngitis, tonsillitis and acute bacterial sinusitis. Community-acquired pneumonia of mild to moderate severity (excluding atypical pneumonia). Symptomatic lower urinary tract infections, including cystitis.

Skin and skin structure infections.

NOTE: 1. Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. KARLOR CD is generally effective in the eradication of streptococci from the oropharynx; however, substantial data establishing the efficacy of KARLOR CD in the subsequent prevention of rheumatic fever are not available. 2. Bacteriologic studies to determine the causative organism and its susceptibility to cefaclor should be performed. Therapy may be started while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly.

KEFLEX is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by S. pneumoniae and group A beta-haemolytic streptococci (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. KEFLEX is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of KEFLEX in the subsequent prevention of rheumatic fever are not available at present.) Bacterial sinusitis caused by streptococci, S. pneumoniae and S. aureus (methicillin-sensitive only) Otitis media due to S. pneumoniae, staphylococci Skin and soft-tissue infections caused by staphylococci and/or streptococci Genitourinary tract infections, including acute prostatitis caused by E. coli, P. mirabilis, and Klebsiella sp. The effectiveness of KEFLEX in the treatment of bacterial infections of the brain and spinal column has not been established and KEFLEX is not indicated in these conditions. NOTE: Appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to KEFLEX. Renal function studies should be performed when indicated.

KEFLIN is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below.

Culture and susceptibility studies should be performed. Therapy may be instituted before results of susceptibility studies are obtained.

Respiratory tract infections caused by S. pneumoniae, staphylococci (penicillinase and non-penicillinase-producing), group A beta-haemolytic streptococci, Klebsiella, and H. influenzae.

Skin and soft-tissue infections, including peritonitis, caused by staphylococci (penicillinase and non-penicillinase-producing), group A beta-haemolytic streptococci, E. coli, Pr. mirabilis, and Klebsiella.

Genito-urinary tract infections caused by E. coli, Pr. mirabilis and Klebsiella.

Septicaemia, including endocarditis, caused by S. pneumoniae, staphylococci (penicillinase and non-penicillinase-producing), group A beta-haemolytic streptococci, S. viridans; E. coli, Pr. mirabilis, and Klebsiella.

Bone and joint infections caused by staphylococci (penicillinase and non- penicillinase-producing).

Prophylactically in vaginal hysterectomy, head and neck surgery, insertion of prosthetic heart valves, and prosthetic arthroplasty. Cefalotin is not recommended for G.I. procedures or other sites where anaerobic organisms such as bacteroides tend to prevail. Dosage is required pre-, intra- and post- operatively (i.e. perioperatively ).

If signs of postoperative infection develop, specimens should be cultured to identify the causative organism so that appropriate therapy can be instituted.

NOTE: If the susceptibility tests show that the causative organism is resistant to KEFLIN, other appropriate antibiotic therapy should be instituted.

Kefzol is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory tract infections due to S. pneumoniae, Klebsiella species, H. influenzae, Staph. aureus (penicillin-sensitive and penicillin- resistant), and Group A beta-haemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Kefzol is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Kefzol in the subsequent prevention of rheumatic fever are not available at present. Genitourinary tract infections due to Esch. coli, Pr. mirabilis, Klebsiella species, and some strains of Enterobacter and enterococci. Skin and skin structure infections due to Staph. aureus (penicillin-sensitive and penicillin- resistant), and Group A beta-haemolytic streptococci and other strains of streptococci. Bone and joint infections due to Staph. aureus. Septicaemia due to S. pneumoniae, Staph. aureus (penicillin-sensitive and penicillin-resistant), Pr. mirabilis, Esch. coli and Klebsiella species. Endocarditis due to Staph. aureus (penicillin-sensitive and penicillin- resistant), and Group A beta-haemolytic streptococci. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to Kefzol.

Kenacomb is indicated for the relief of the inflammatory and pruritic manifestations of dermatoses likely to become or which are all ready infected.

Kenacomb Otic is indicated for the treatment of otitis externa (acute and chronic) when a topical corticosteroid is required and active infections with susceptible organisms are either present or likely to supervene. Kenacomb Otic is only recommended for short-term use.

Intra-Articular: Kenacort-A 10 Injection (Sterile Triamcinolone Acetonide Suspension USP) is indicated for intra-articular or intrasynovial administration, and for injections into tendon sheaths, as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: synovitis of osteoarthritis, rheumatoid arthritis, acute and subacute bursitis, acute gouty arthritis, epicondylitis, acute nonspecific tenosynovitis, post-traumatic osteoarthritis. Intradermal: Intralesional administration of Kenacort-A 10 Injection is indicated for the treatment of keloids, discoid lupus erythematous, necrobiosis lipoidica diabeticorum, alopecia areata and localised hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis), Kenacort-A 10 Injection also may be useful in cystic tumours of an aponeurosis or tendon (ganglia).

Intramuscular: The intramuscular administration of Kenacort-A 40 (Sterile Triamcinolone Acetonide Suspension USP) is indicated for systemic corticosteroid therapy in such conditions as allergic diseases, dermatoses, or generalised rheumatoid arthritis and other connective tissue disorders. Intramuscular administration is particularly valuable in such conditions when oral corticosteroid therapy is not feasible. Intra-Articular: Kenacort-A 40 Injection (Sterile Triamcinolone Acetonide Suspension USP) is indicated for intra-articular or intrasynovial administration, and for injections into tendon sheaths, as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in; synovitis of osteoarthritis; rheumatoid arthritis; acute and subacute bursitis; acute gouty arthritis; epicondylitis; acute nonspecific tenosynovitis; post-traumatic osteoarthritis.